Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu
Phase 1
- Conditions
- Safety Issues
- Interventions
- Biological: LD Universal Influenza Vaccine UnifluBiological: PlaceboBiological: HD Universal Influenza Vaccine Uniflu
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- VA Pharma Limited Liability Company
- Target Recruit Count
- 54
- Registration Number
- NCT03789539
- Locations
- 🇷🇺
Research Institute of Influenza, Sankt-Petersburg, Saint-Petersburg, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath